Meridian Bioscience Inc (VIVO) 16.36 $VIVO
Meridian Bioscience (VIVO) Downgraded From Buy to Hold
at The Street - Thu Dec 11, 5:50AM CST
Meridian Bioscience (VIVO) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
VIVO: 16.36 (-0.35)
Meridian Bioscience Has Returned 15.8% Since SmarTrend Recommendation (VIVO)
Comtex SmarTrend(R) - Tue Dec 09, 9:32AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 15.79% as of today's recent price of $16.51.
VIVO: 16.36 (-0.35)
Meridian Bioscience: A Strong Sell on Dismal Q4, Competition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 12:40PM CST
On Dec 2, 2014, Zacks Investment Research downgraded diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) to a Zacks Rank #5 (Strong Sell).
ICUI: 80.95 (-1.04), INSY: 41.00 (+1.82), VIVO: 16.36 (-0.35), OSUR: 9.49 (-0.25)
Dividend Dogs Of Healthcare: A 29.17% Advantage For The 5 Lowest Price High Yield Stocks
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 8:37AM CST
SNN: 32.48 (-0.41), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), THRX: 13.39 (-0.37), GSK: 42.42 (-0.93), SNY: 45.16 (-1.05), PDLI: 7.41 (-0.08)
5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 2:40AM CST
KND: 18.61 (+0.54), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), GSK: 42.42 (-0.93), MSA: 51.14 (-0.88), HLS: 37.46 (-1.14), SEM: 13.95 (-0.28), PDLI: 7.41 (-0.08), SNN: 32.48 (-0.41), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), TRIB: 16.55 (-0.17), TEVA: 55.92 (-0.92), THRX: 13.39 (-0.37), SNY: 45.16 (-1.05)
Meridian Life Science Awarded SBIR II by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine
Business Wire - Tue Dec 02, 5:00AM CST
Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce they have been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development will focus on optimization of growth and yield of the virus in cell culture, developing and characterizing a column-based purification process followed by formulation, inactivation and filling of the vaccine. This SBIR II, which follows an initial SBIR I awarded to MLS in 2013, will fund a 15 month research and development effort leading to scale up and manufacture of a rotavirus vaccine for use in clinical trials. MLS is a contract manufacturer offering production of vaccines and challenge stocks which employ current Good Manufacturing Practices (cGMP) as described in 21 CFR Parts 210 and 211.
VIVO: 16.36 (-0.35)
Downtrend Call Working As Meridian Bioscience Stock Falls 15.8% (VIVO)
Comtex SmarTrend(R) - Mon Dec 01, 4:58PM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 15.79% as of today's recent price of $16.51.
VIVO: 16.36 (-0.35)
Insider Trading Alert - VIVO, HTA And NTWK Traded By Insiders
at The Street - Tue Nov 25, 11:51AM CST
Stocks with insider trader activity include VIVO, HTA and NTWK
VIVO: 16.36 (-0.35), NTWK: 3.90 (-0.11), HTA: 13.06 (+0.01)
17.9% Return Seen to Date on SmarTrend Meridian Bioscience Call (VIVO)
Comtex SmarTrend(R) - Mon Nov 24, 11:14AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 17.88% as of today's recent price of $16.10.
VIVO: 16.36 (-0.35)
Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST
VIVO: 16.36 (-0.35), TMO: 124.99 (-1.73), EXAS: 27.96 (-0.24)
Healthcare's Top Dividend Paying Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 13, 6:43AM CST
Source: Flickr user TaxRebate.org.uk. Dividends are the foundation to which all great long-term portfolio are built. Receiving a payment equal to 2% or 3% per year might not seem like much, but reinvested into that same growing company over the...
VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), GSK: 42.42 (-0.93), SNY: 45.16 (-1.05), PDLI: 7.41 (-0.08)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.00 (+0.11), VIVO: 16.36 (-0.35), ABAX: 57.20 (+0.61), OSUR: 9.49 (-0.25)
Meridian Bioscience Down 13.7% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Mon Nov 10, 9:45AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 13.75% as of today's recent price of $16.91.
VIVO: 16.36 (-0.35)
Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.36 (-0.35), ABAX: 57.20 (+0.61), GWPH: 72.41 (+1.18), OSUR: 9.49 (-0.25)
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Fri Nov 07, 6:59AM CST
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $17.91 on volume of 374,000 shares, above average daily volume of 203,000. Over the past year, Meridian Bioscience has traded in a range of $17.12 to $27.72 and closed yesterday at $17.91, 5% above that low. The 200-day and 50-day moving averages have moved 0.73% lower and 0.51% lower over the past week, respectively.
VIVO: 16.36 (-0.35)
Meridian Bioscience misses Street 4Q forecasts
Automated Insights - Thu Nov 06, 10:18AM CST
CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Thursday reported fiscal fourth-quarter net income of $8.2 million.
VIVO: 16.36 (-0.35)
Meridian Bioscience declares $0.20 dividend
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VIVO: 16.36 (-0.35)
Meridian Bioscience misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:02AM CST
VIVO: 16.36 (-0.35)
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
Business Wire - Thu Nov 06, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO):
VIVO: 16.36 (-0.35)
Meridian Bioscience (VIVO) Downgraded From Buy to Hold
at The Street - Thu Dec 11, 5:50AM CST
Meridian Bioscience (VIVO) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
VIVO: 16.36 (-0.35)
Meridian Bioscience Has Returned 15.8% Since SmarTrend Recommendation (VIVO)
Comtex SmarTrend(R) - Tue Dec 09, 9:32AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 15.79% as of today's recent price of $16.51.
VIVO: 16.36 (-0.35)
Meridian Bioscience: A Strong Sell on Dismal Q4, Competition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 12:40PM CST
On Dec 2, 2014, Zacks Investment Research downgraded diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) to a Zacks Rank #5 (Strong Sell).
ICUI: 80.95 (-1.04), INSY: 41.00 (+1.82), VIVO: 16.36 (-0.35), OSUR: 9.49 (-0.25)
Dividend Dogs Of Healthcare: A 29.17% Advantage For The 5 Lowest Price High Yield Stocks
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 8:37AM CST
SNN: 32.48 (-0.41), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), THRX: 13.39 (-0.37), GSK: 42.42 (-0.93), SNY: 45.16 (-1.05), PDLI: 7.41 (-0.08)
5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 2:40AM CST
KND: 18.61 (+0.54), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), GSK: 42.42 (-0.93), MSA: 51.14 (-0.88), HLS: 37.46 (-1.14), SEM: 13.95 (-0.28), PDLI: 7.41 (-0.08), SNN: 32.48 (-0.41), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), TRIB: 16.55 (-0.17), TEVA: 55.92 (-0.92), THRX: 13.39 (-0.37), SNY: 45.16 (-1.05)
Meridian Life Science Awarded SBIR II by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine
Business Wire - Tue Dec 02, 5:00AM CST
Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce they have been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development will focus on optimization of growth and yield of the virus in cell culture, developing and characterizing a column-based purification process followed by formulation, inactivation and filling of the vaccine. This SBIR II, which follows an initial SBIR I awarded to MLS in 2013, will fund a 15 month research and development effort leading to scale up and manufacture of a rotavirus vaccine for use in clinical trials. MLS is a contract manufacturer offering production of vaccines and challenge stocks which employ current Good Manufacturing Practices (cGMP) as described in 21 CFR Parts 210 and 211.
VIVO: 16.36 (-0.35)
Downtrend Call Working As Meridian Bioscience Stock Falls 15.8% (VIVO)
Comtex SmarTrend(R) - Mon Dec 01, 4:58PM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 15.79% as of today's recent price of $16.51.
VIVO: 16.36 (-0.35)
Insider Trading Alert - VIVO, HTA And NTWK Traded By Insiders
at The Street - Tue Nov 25, 11:51AM CST
Stocks with insider trader activity include VIVO, HTA and NTWK
VIVO: 16.36 (-0.35), NTWK: 3.90 (-0.11), HTA: 13.06 (+0.01)
17.9% Return Seen to Date on SmarTrend Meridian Bioscience Call (VIVO)
Comtex SmarTrend(R) - Mon Nov 24, 11:14AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 17.88% as of today's recent price of $16.10.
VIVO: 16.36 (-0.35)
Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST
VIVO: 16.36 (-0.35), TMO: 124.99 (-1.73), EXAS: 27.96 (-0.24)
Healthcare's Top Dividend Paying Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 13, 6:43AM CST
Source: Flickr user TaxRebate.org.uk. Dividends are the foundation to which all great long-term portfolio are built. Receiving a payment equal to 2% or 3% per year might not seem like much, but reinvested into that same growing company over the...
VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), GSK: 42.42 (-0.93), SNY: 45.16 (-1.05), PDLI: 7.41 (-0.08)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.00 (+0.11), VIVO: 16.36 (-0.35), ABAX: 57.20 (+0.61), OSUR: 9.49 (-0.25)
Meridian Bioscience Down 13.7% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Mon Nov 10, 9:45AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 13.75% as of today's recent price of $16.91.
VIVO: 16.36 (-0.35)
Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.36 (-0.35), ABAX: 57.20 (+0.61), GWPH: 72.41 (+1.18), OSUR: 9.49 (-0.25)
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Fri Nov 07, 6:59AM CST
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $17.91 on volume of 374,000 shares, above average daily volume of 203,000. Over the past year, Meridian Bioscience has traded in a range of $17.12 to $27.72 and closed yesterday at $17.91, 5% above that low. The 200-day and 50-day moving averages have moved 0.73% lower and 0.51% lower over the past week, respectively.
VIVO: 16.36 (-0.35)
Meridian Bioscience misses Street 4Q forecasts
Automated Insights - Thu Nov 06, 10:18AM CST
CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Thursday reported fiscal fourth-quarter net income of $8.2 million.
VIVO: 16.36 (-0.35)
Meridian Bioscience declares $0.20 dividend
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VIVO: 16.36 (-0.35)
Meridian Bioscience misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:02AM CST
VIVO: 16.36 (-0.35)
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
Business Wire - Thu Nov 06, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO):
VIVO: 16.36 (-0.35)
